Completed PHASE2 INTERVENTIONAL 1-arm NCT01847521

Effects of the Anti-inflammatory Flavonoid Luteolin on Behavior in Children With Autism Spectrum Disorders

Sponsor: Attikon Hospital

Interventions Luteolin, Quercetin and Rutin combined in a capsule

Updated 7 times since 2017 Last updated: May 2, 2013 Started: Dec 31, 2011 Primary completion: Feb 28, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Autism Spectrum Disorders, this trial is completed. The trial is conducted by Attikon Hospital and has accumulated 7 data snapshots since 2011. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Attikon Hospital

Data source: Attikon Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chaïdári, Greece